U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Drug developer NextCure said on Monday it had signed a deal worth up to $745 million with China-based drugmaker Simcere Zaiming to develop a cancer therapy for solid tumors.

Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with ...

Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug ... billion deal with China’s ...

China has vowed to fight back over what it called “discriminatory restrictive measures” by the U.S. that it said are endangering an agreement hammered out between the two countries last month.

Senators Bernie Sanders and Angus King are preparing to introduce legislation that would ban pharmaceutical companies from advertising prescription drugs directly to consumers, The Wall Street Journal ...

Hours earlier, Trump's Treasury chief said negotiations between the two nations on a longer-term deal are in a rut. “The bad news is that China, perhaps not surprisingly to some, HAS TOTALLY ...

AI data centers need energy, and that’s what’s made the stock price of aptly-named NRG $NRG rise 88% in the past year ...